No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
ESPR Esperion Therapeutics
- 2.130
- +0.040+1.91%
Close Apr 24 16:00 ET
- 2.140
- +0.010+0.47%
Pre 05:45 ET
403.42MMarket Cap-1049P/E (TTM)
2.160High2.060Low5.68MVolume2.110Open2.090Pre Close12.03MTurnover3.02%Turnover RatioLossP/E (Static)189.40MShares3.40052wk High-0.89P/B401.19MFloat Cap0.70052wk Low--Dividend TTM188.35MShs Float120.960Historical High--Div YieldTTM4.79%Amplitude0.700Historical Low2.115Avg Price1Lot Size
Pre-Market
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Esperion to Report First Quarter 2024 Financial Results on May 7
Esperion (NASDAQ: ESPR) today announced it will report first quarter 2024 financial results before the market opens on Tuesday, May 7, 2024.
Applied Digital Reports Downbeat Results, Joins Nurix Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling over 50 points on Friday. Shares of Applied Digital Corporation (NASDAQ:APLD) fell sharply in today's pre-market trading after
Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Fastenal Company (NASDAQ:FAST) fell sharply during Thursday's session following worse-than-expected first-quarter financial results. Fastenal reported first-quarter FY24 sales growth of 1.9
Express News | Esperion Therapeutics Shares Are Trading Lower. The Company Announced the Presentation of New Data From CLEAR Outcomes
Why Esperion Therapeutics Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) shares rose sharply during today's pre-market trading after the company presented new data from CLEAR outcomes at ACC.24 highlighting value of NEX
Reported Sunday, Esperion Presents New Data From CLEAR Outcomes At ACCR 2024 Highlighting Value Of NEXLETOL Tablets In Diverse Populations
Patients With Obesity Who Took NEXLETOL Were 23% Less Likely to Experience a Major Adverse Cardiovascular Event (MACE-4) Compared to PlaceboNEXLETOL Demonstrated Clinical Benefit in Historically Under
Comments
$Esperion Therapeutics(ESPR.US$ seems like a good time To jump in
ESPR is the Probably the Most Undervalued Stock on the Market, Offers 2500% Upside. 2 FDA Approved Blockbuster Drugs. Billions in Sales Expected. Buyout Expected.
$Esperion Therapeutics(ESPR.US$ Esperion (ESPR) stock price has dropped from a recent high of $3.40 a share to $2.31 on FALSE claims of dilution. The price drop offers an amazing buying opportunity.
Huge News On Mar 25.2024 U.S. FDA Approved Broad Labels for NEXLIZET and NEXLETOL, now regular doctors can prescribe and Insurance will...
Huge News On Mar 25.2024 U.S. FDA Approved Broad Labels for NEXLIZET and NEXLETOL, now regular doctors can prescribe and Insurance will...
3
Hmm? Weight loss with DEI kicker and it’s down! Hehehe! I get it today is Opposite Day! Hehehe!
$Esperion Therapeutics(ESPR.US$ Patients With Obesity Who Took NEXLETOL Were 23% Less Likely to Experience a Major Adverse Cardiovascular Event (MACE-4) Compared to Placebo –
– NEXLETOL Demonstrated Clinical Benefit in Historically Underrepresented Groups: Women and Hispanic/Latinx Patients With and Without Cardiovascular Disease (CVD) –
– CLEAR Outcomes Sets New Standards for Diversity and Inclusion ...
– NEXLETOL Demonstrated Clinical Benefit in Historically Underrepresented Groups: Women and Hispanic/Latinx Patients With and Without Cardiovascular Disease (CVD) –
– CLEAR Outcomes Sets New Standards for Diversity and Inclusion ...
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg